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Inclusion complexes of rifampicin (RP) were prepared with
hydroxypropyl-β-cyclodextrin (HPβCD). The aqueous solubility of
RP increased linearly with cyclodextrin concentration in all range
of the solubility diagram. The data was analyzed using the
framework of Higuchi and Connors. The stability constant (K)
values for RP/HPβCD complex at pH 6.9 were 18 and 120-125 M-1
for ionic strength 0.01 and 0.18M, respectively. The analysis of the
chemical shift data of 1H and 15N for free RP and RP/HPβCD
inclusion complex reveal that only peaks of the side chain related
to the piperazine ring of RP change substantially, probably due to
interaction of this region of RP molecule with the hydrophobic core
of HPβCD. We also postulated the optimized structure of RP/
HPβCD inclusion complex using molecular modelling study. We
found that the postulated structure was in agreement with 1H and
13C-NMR and 15N-NMR spectra.
* Correspondence:
A.G. Oliveira
Departamento de Fármacos e
Medicamentos.
Faculdade de Ciências Farmacêuticas
UNESP
Rodovia Araraquara-Jaú km 01








• Proton Nuclear Magnetic
• Resonance
INTRODUCTION
Rifampicin (RP) is a wide-spectrum antibiotic
active against the most Gram-positive bacteria and
variable active against Gram-negative microrganisms.
Due to the development of resistance to rifampicin by
many bacteria its clinical use is mainly in the treatment of
tuberculosis (Reynolds, 1993). RP (Figure 1) is a potent
inductor of the cytochrome P-450 of the hepatic and intes-
tinal enzymatic system and of P-glycoprotein of the
transport system, which results in numerous drug
interactions and side effects (Watcher et al., 1998; Achira
et al., 1999). Thus, the interaction of RP with drug carriers
to improve effectiveness and minimize side effects is of
obvious relevance.
The ability of cyclodextrins (CD) to modify
physicochemical properties of drugs or issues of drug
toxicity is well known (Loftsson, Brewster, 1996;
Montassier et al., 1997). Because the chemical structure
of the molecule, cyclodextrin includes a central
hydrophobic cavity and an outer hydrophilic surface. The
hydrophobic inner of cavity is a result of the electron rich
environment caused mainly by the glycosidic oxygen
atoms. The group of forces, including Van der Waals,
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hydrogen bonds and hydrophobic effects contribute to the
formation of a stable complex of drugs in the apolar cavity
of cyclodextrins (Bibby et al., 2001). Thus, a large number
of drug molecules can be complexed to CD modifying
solubility, bioavaila bility and stability (Loftsson et al.,
1991; Vianna et al., 1998; Dalmora, Oliveira, 1999;
Dalmora et al., 2001; Loftsson et al., 2001; Másson et al.,
1998). Important reviews on cyclodextrin applications in
the pharmaceutical field were published with details
(Bibby et al., 2001; Hirayama, Uekama, 1999; Szejtli,
1994; Loftsson, Másson, 2001).
Several experimental procedures have been used to
analyze the structural and thermodynamic parameters
related to cyclodextrin inclusion complex formation
(Goyenechea, et al., 2001; Connors, 1997; Bobec et al.,
2000; Díaz et al., 1999; Myake et al., 1999). Experimen-
tal procedures using NMR (Másson et al., 1998; Díaz et
al., 1999; Loukas, 1997; Myake et al., 1999), solubility
analysis and UV-Vis spectroscopy (Dalmora, Oliveira,
1999; Oh et al., 1998), molecular mechanical calculations
(Montassier et al., 1997; Vianna et al., 1998; Bobek et al.,
2000; Madri, et al., 1997; Myles et al., 1994), DSC study
(Bermúdez et al., 1999) and X-ray diffraction (Montassier
et al., 1997; Bobek et al., 2000) are frequently used to
elucidate the structure of molecular complexes.
In this work we have studied the increase of the
solubility of rifampicin by molecular complexation with
hydroxypropyl-β-cyclodextrin. Molecular Modelling
study of the structure of HPβCD, rifampicin and RP/
HPβCD inclusion complexes were performed. The
molecular complexes were also analysed by 1H, 13C and
15N-NMR spectroscopy in order to characterize the
structure of the inclusion complex.
MATERIAL AND METHODS
Material
Hydroxypropyl-β-cyclodextrin (HPßCD), D.S. 4.6,
was purchased from CTD Inc., Florida, USA. Rifampicin
(RP) [3-(4-methylpiperazinyl-iminomethyl]rifamycin and
deuterium oxide (D2O), were obtained from Sigma Chemical
Company, St. Louis, MO, USA. Reagents used for the
preparations of citrate and Tris-HCl buffer, were analytical
grade. Double distillate and deionised water were used in all
experiments. All others reagents were analytical grade.
Methods
Stability Constant Determination
Amounts of RP (about 300 mg) that exceeded its
solubility were weighed in a 25 mL plastic flask, to which
10 mL of buffer solution (pH 6.9) containing HPβCD with
concentrations in the range of 0-100 mM was added. The
mixture was kept under agitation by 24 hours at controlled
temperature of 25 °C to reach steady state. Then, the ma-
terial was filtered through 0.22 µm membrane. Afterwards
appropriate dilution with buffer solution was performed
and the concentration of rifampicin was measured by
spectrophotometry at 331 nm. The solubility diagram was
plotted, relating the absorbance as a function of dissolved
rifampicin. The stability constant (K) was calculated using
the framework of Higuchi and Connors model (Higuchi,
Connors, 1965):
K
RPf + HPβCD    RPb (1)
Where K is the stability constant for RP/HPbCD 1:1
complex and the subscripts f and b refer to the free and
bound RP, respectively.
K = slope/So (1 – slope)  (2)
Where slope is calculated from of the linear phase
solubility diagram, and So is the intrinsic apparent
solubility of RP in the absence of cyclodextrin.
The effect of the buffer and ionic strength on the
formation of RP complexes were carried out in citrate
buffer pH 6.9, µ =180 mM and in Tris-HCl buffer pH 6.9,
µ =10 mM and 180 mM. The ionic strength was adjusted
using sodium chloride.
Molecular Modelling Studies
A model of inclusion complex was investigated
FIGURE 1 - Chemical structure of rifampicin.
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through molecular graphic software using the Chem 3D
Ultra software, version 6.0, serial number 553923 with use
authorized by Cambridge Software Corporation (http://
www.cambridgesoft.com/products/ family.cfm?FID=3,
2004). The structures of RP and HPβCD were built
separately, and the conformational energy was minimized
using MM2 method and force field (Schupfer, Gulacar,
2001). A set of structures of minimum-energy was chosen,
and the molecule of RP was introduced into cavity of
HPβCD using docking method. Steric and electrostatic
interactions between the molecules were calculated by
moving the atoms of the molecules back and forth. For the
simulation solvents were not considered. Following, the
atoms of RP and HPßCD were allowed to move freely, and
the most stable docking position of the two molecules was
obtained.
Nuclear Magnetic Resonance (NMR) Measurements
NMR measurements of liquid HPßCD inclusion
complex were taken at 298°K on a Bruker 9.4 Tesla DRX
400 (400 MHz for hydrogen frequency), using as external
reference TSPAd4 to 
1H and 13C and CH3NO2 to 
15N
experiments. A 5 mm probe with inverse detection,
gradient coil in z direction and D2O as a solvent were used.
The 13C and 15N chemical experiments were performed
using gHSQC and gHMBC techniques. For gHMBC
experiments the coupling constants were optimised to 4,
8 and 16 Hz for 13C and also 15N.
The complex was prepared in D2O buffer, as well as
the free rifampicin and CD’s. The spectra were recorded
at the following conditions:
Hydrogen: The spectrum was recorded using a
pulprog zgpr, acquisition time 5.1 s, 90o pulse width 8.3
µs, spectral width 6377 Hz, relaxation delay 1s and
acquired 128 scans. They were processed using zero
filling and without any window function.
COSY: The spectrum was obtained using a pulse
sequence cosygs, with acquisition time 0.16 s, 90o pulse
width 8.3 µs, spectral width 6377 Hz, relaxation delay 1.2
s, acquired 16 scans and 256 experiments. It was
processed using SINE apodization function and zero
filling in both dimensions.
gHSQC: The spectrum was recorded using a pulse
sequence inviestgssi, acquisition time 0.16 s, 90o pulse
width 8.3 and 12.0 µs for 1H and 13C respectively, relaxation
delay 1.2 s, spectral widths 6377 and 18000 Hz for F2 and
F1 dimension, 64 scans and 256 experiments. It was
processed using QSINE apodization function (SSB=3 for
booths dimensions) a zero filling in F2 and F1 dimension.
gHMBC 1H-13C: The spectra were recorded using a
pulse sequence inv4gslplrnd, acquisition time 0.16 s, 90o
pulse widths 8.3 and 12.0µs for 1H and 13C respectively,
relaxation delay 1.2 s, spectral widths 6377 and 18000 Hz
for F2 and F1 dimension, 64 scans and 256 experiments.
It was processed using QSINE apodization function
(SSB=2 for both dimensions) a zero filling in F2 and F1
dimension.
gHMBC 1H-15N: The spectra were recorded using a
pulse sequence inv4gslrnd, acquisition time 0.26 s, 90o
pulse widths 8.3 and 20.4 µs for 1H and 15N respectively,
relaxation delay 2 s, spectral widths 8012 and 20249 Hz
for F2 and F1 dimension, 1024 scans and 34 experiments.
It was processed using QSINE apodization function
(SSB=2 for booths dimensions) a zero filling in F2 and F1
dimension
RESULTS
The analysis of the drug inclusion complex with
cyclodextrin in solution can be achieved by several
methods. The analysis of the drug solubilization
associated to spectral changes can be used to measure the
transference of the drug from the aqueous phase to the
apolar cavity of cyclodextrin. If the drug has limited
aqueous solubility, the concentration of solubilized drug
can be increased by the inclusion in cyclodextrin.
In our results, linear responses of rifampicin
concentrations dissolved against HPβCD concentrations
can be observed (Figure 2).
The phase solubility behaviors show that rifampicin
followed the AL type phase solubility diagram (Másson et
al., 1998) indicating that the stoichiometry of molecular
complex between RP/HPβCD was probably 1:1.
Using the equation de Higuchi and Connors, the
calculated results for K were 18 M-1 for 10 mM Tris-HCl
buffer ionic strength 10 mM. For 30 mM citrate and 10
mM Tris-HCl buffer ionic strength 0.18 M, the values
obtained for K were 120 M-1 and 125 M-1, respectively.
From the results of the molecular modelling
calculations for RP/HPβCD complexes it is possible to
predict that the piperazine side chain of RP enclosed into
HPβCD hydrophobic cavity can form the complex or with
the bulkiest region of RP molecule enclosed into
cyclodextrin cavity. The calculations of the minimisation
energy for inclusion complex for both cases, by MM2
method, provided the values of 330 kcal/mol and 1113
kcal/mol, respectively. These results indicate that the most
stable complex (due to less energy value) have the
rifampicin complexed with HPβCD through the
piperazine tail enclosed into the hydrophobic cavity of
HPβCD and the bulky region of the molecule in the
surface cavity of cyclodextrin (Figure 3).
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Nuclear magnetic resonance study at high field has
been used to investigate the stoichiometries of important
drug inclusion complexes. This technique provides
evidence for the existence of true inclusion complexes and
allows unequivocal determination of the stoichiometry for
complexes obtained in the solid state, as well as in solution
(Djedaini, Perly, 1991). For the analysis of the spectra of
the figures 4-7, we have used the RP structure of figure 1.
We can verify in the Figure 4 that for pure RP the
signal of hydrogen 46 at δ = 2.91 ppm is a singlet coupled
to carbon 46 (δ = 45.8 ppm). The arrow indicates the
correlation signal for 1H-13C.
The spectra of Figure 5 characterizes the
identification of the multiplet of hydrogen 46 coupled to
carbon 46 which suggests that this region of the RP
molecule is one site of interaction between RP and CD.
Figure 6 shows the RP spectra with the correlations
values obtained by HMBC for the bounds 1H-15N. It is
possible to see the hydrogen 38 (δ = 3.23 ppm) coupled to
N39 (δ = 350 ppm) and with N40 of the piperazine ring
(δ = 114 ppm).
The variation of the chemical displacement of the
N40 (δ =150 ppm) coupled to hydrogen 38 for the RP
complex with CD can be seen in Figure 7. This chemical
displacement suggests that this region of RP molecule
interacts with the cyclodextrin in the inclusion complex.
DISCUSSION
Although rifampicin has a bulky structure, the
values of stability constants for the antibiotic (18 M-1 for
µ=0.01 and 120-125 M-1 for µ=0.18) show that the
inclusion complexes are formed and that the solubility of
antibiotic in the presence of hydroxypropyl-β-
cyclodextrin increase about 6 fold in high ionic strength
independently of the buffer system used. This
FIGURE 2 - Solubility diagram of rifampicin with HPβCD at 25 °C. Key: ( ) 30 mM citrate buffer, pH 6.9, µ=180 mM;
( ) 10 mM Tris-HCl buffer, pH 6.9, µ=10 mM; ( ) 10 mM Tris-HCl buffer, pH 6.9, µ=180 mM. The ionic strength
was adjusted with sodium chloride.
FIGURE 3 - Molecular Model of RP inclusion complex
with hydroxypropyl-β-cyclodextrin. Key (A) HPβCD
molecule; (B) Rifampicin molecule.
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FIGURE 4 - gHSQC 1H-13C spectrum of the pure RP with magnification of the region of H46. The arrow indicates the
correlation signal for 1H-13C.
FIGURE 5 - gHSQC 1H-13C spectrum of the RP/HPβCD molecular complex with magnification of the H46 region.
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FIGURE 6 - gHMBC 1H-15N spectrum of pure rifampicin.
FIGURE 7 - gHMBC 1H-15N spectra of molecular complex RP/HPβCD.
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phenomenon can be understood since at pH 6.9 the
antibiotic is a zwiterion and binds to cyclodextrin cavity
by hydrophobic effect. Thus, the activity coefficient of
neutral organic compounds increases with ionic strength
of medium and therefore favours the transfer of the drug
from hydrophilic medium to hydrophobic cavity of
cyclodextrin increasing the value of the stability constant
(Oliveira et al., 1997).
We have shown that MM2 Molecular Modelling
calculations for RP/CD complex using computational
tools demonstrate the experimental evidence that the
complex at molar ratio 1:1 are thermodynamically stable.
For RP/HPβCD complex of minimum energy it was
possible to predict that the piperazine tail of RP penetrates
into cyclodextrin cavity through hydrophobic interactions.
However, the low values obtained for K indicate a weak
bond of RP into HPβCD molecule, probably due to steric
hindrance of the substitutive hydroxypropyl group of
cyclodextrin, which do not allow the approach of the
bulkiest region of RP molecule.
NMR studies were used to compare the chemical
shift of 1H and 13C of rifampicin with a similar compound
from literature (Fuhrer von, 1973). However, since the
D2O solubility of rifampicin was not good to obtain a
direct detection of 13C chemical shift and the data of
literature were obtained in deuterated methanol, we have
adopted the inverse detection approach.
Comparing the chemical shift data of 1H and 15N for
free RP and RP/HPßCD complex it was verified that only
peaks of the side chain related to the piperazine ring
change substantially. In fact, the data of table I show that
the RP hydrogen in the positions 38 (δ 8.10 1H s) and 46
(δ 2.91 3H s) change to (8,17 bs) and (2.76-2.88 m),
respectively (Table I).
In addition, it is possible to verify that not only occur
the chemical shift but also a clear multiplicity in the signal
of hydrogen 46 coupled to carbon 46. On the other hand,
the 15N chemical shift for N40 changes from d 114 for free
RP to 150 ppm for RP/HPßCD complex. All the carbons
and hydrogens attributions are in agreement with the data
founded in the literature (Fuhrer von, 1973; Gallo, et al.,
1974) although the authors have used different solvents.
Thus, this group of data obtained by 2D-NMR allow
suggesting that the RP was complexed with the HPßCD
through the lateral chain containing piperazine ring and
that the geometry of the complex is in agreement with the
predictions of the Molecular Modelling Calculations.
CONCLUSIONS
The increase in the aqueous solubility of RP caused
by the presence of HPbCD was dependent on the ionic
strength and is one of experimental evidence of the
molecular complexation. The spectroscopy analysis by 1H
and 15N NMR showed that the signals of the hydrogen at
C38 and C46 of RP were shifted upfield due to interaction
with HPßCD. The postulated structure of complex RP/
HPbCD was in agreement with 1H and 13C-NMR and 15N-
NMR spectra.
RESUMO
Análise da associação molecular da rifampicina com
hidroxipropil-β-ciclodextrina
Foram preparados complexos de inclusão de rifampicina
(RP) com hidroxipropil-β-ciclodextrina (HPβCD). A so-
lubilidade da RP em água aumentou linearmente com a
concentração de ciclodextrina na faixa de concentração
utilizada no diagrama de solubilidade. Os resultados fo-
ram analisados quantitativamente através do modelo de
Higuchi e Connors. Os valores da constante de estabilida-
de (K) para o complexo RP/HPβCD em pH 6,9 foram 18
e 120-125 M-1 para as forças iônicas 0,01 e 0,18 M, res-
pectivamente. A análise dos dados de deslocamento quí-
mico de 1H e 15N-NMR para a RP livre e do complexo de
inclusão RP/HPβCD revelou que somente os picos da
cadeia lateral relacionada com o anel piperazina modifi-
caram substancialmente, provavelmente devido à
interação desta região da molécula da RP com a cavida-
de hidrofóbica da HPβCD. Com base no estudo de mode-
lagem molecular foi proposta a estrutura otimizada para
o complexo de inclusão RP/HPβCD. A estrutura propos-
ta está de acordo com os resultados dos espectros de 1H e
13C-NMR e 15N-NMR .
UNITERMOS:  Rifampicina. Hidroxipropil-ß-
ciclodextrina. Complexo de inclusão. Modelagem
molecular. Ressonância Nuclear Magnética.
TABLE I - Chemical shift δ (ppm) of 1H NMR for RP/
HPβCD inclusion complex
Atom Free RP RP/HPβCD
number* D2O 298 oK complex
D2O** 298 oK
38 8.10 1H s 8.17 bs
46 2.91 3H s 2.76-2.88 m
*See figure 1; ** TSPA-d4 was used as external reference
in all spectra.
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